Novartis | NVS - Ebitda


Novartis reported $5.84B in EBITDA for its fiscal quarter ending in September of 2025.





Ebitda Change Date
AbbVie USD 5.37B 1.85B Dec/2025
Amgen USD 5.14B 775M Dec/2025
AstraZeneca USD 5.67B 1.29B Mar/2026
Bausch Health Companies USD 837M 94M Mar/2026
Biogen USD 649.7M 76.5M Mar/2026
Bristol-Myers Squibb USD 2.88B 1.36B Dec/2025
Canopy Growth CAD -2.87M 19.49M Dec/2025
Corcept Therapeutics USD 4.2M 6.5M Dec/2025
Drreddys Laboratories INR 21.59B 1.49B Dec/2025
Eli Lilly USD 12.14B 4.26B Dec/2025
Gilead Sciences USD 3.02B 1.01B Dec/2025
GlaxoSmithKline GBP 2.77B 1.65B Mar/2026
Glaxosmithkline GBP 4.75B 1.52B Sep/2025
J&J USD 7.19B 2.32B Dec/2025
Merck USD 6.3B 2.09B Dec/2025
Novartis USD 5.3B 530M Mar/2026
Novartis USD 5.84B 235M Sep/2025
Pacira USD 40.24M 1.53M Mar/2026
Perrigo USD 141.6M 1.34B Mar/2026
Pfizer USD 5.99B 5.23B Mar/2026
Phibro Animal Health USD 68.1M 6.2M Dec/2025
Prestige Brands USD 90.82M 3.99M Dec/2025
Roche Holding CHF 12.68B 2.36B Jun/2024
Sanofi EUR 3.31B 3.65B Mar/2026
Sanofi EUR 5.66B 3.77B Sep/2025
Supernus Pharmaceuticals USD 29.23M 19.27M Mar/2026
Zoetis USD 939M 101M Dec/2025